Neural Correlates of Successful Cognitive Aging

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT02628548
Collaborator
National Institutes of Health (NIH) (NIH), National Institute on Aging (NIA) (NIH)
175
1
2
61.8
2.8

Study Details

Study Description

Brief Summary

Normal aging is associated with gradual cognitive declines. These mild neurocognitive disturbances affect daily functioning, health status, and quality of life, and likely account for the roughly $2.9 billion lost by the elderly each year to fraud. The goal of this project is to compare two different 8-week training programs to promote successful neural and cognitive aging. Changes in neural structure and cognitive function will be assessed in a cohort of older adults, as well as the long-term stability of these changes over 24 months.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive training program
N/A

Detailed Description

Normal aging is associated with gradual cognitive declines. These mild neurocognitive disturbances affect daily functioning, health status, and quality of life, and likely account for the roughly $2.9 billion lost by the elderly each year to fraud. People are paying millions out of pocket for cognitive training programs like Lumosity to stave off these declines. These cognitive decreases have been strongly associated with normal age-dependent declines in neural structure and function, including cortical thickness decreases (approximately 0.02 mm per decade) across most of the cortical mantle, as well as decreases in the volume of the hippocampus (approximately 1-2% annually), white matter microstructure, and functional connectivity across the brain. Life expectancy is increasing and so identifying interventions that can be widely implemented and that can slow or reverse normal cognitive decline are clinical and public health priorities. Some training programs can improve cognitive performance in cognitively normal older adults, and gains are maintained post training. The investigators hypothesize that different techniques to boost cognition likely works through different neural mechanisms, and thus may provide different cognitive benefits. The goal of this project is to compare two different 8-week training programs to promote successful neural and cognitive aging. Changes in neural structure and cognitive function will be assessed in a cohort of older adults, as well as the long-term stability of these changes over 24 months.

Study Design

Study Type:
Interventional
Actual Enrollment :
175 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
Neural and Cognitive Changes Associated With Mental Training in Older Adults
Actual Study Start Date :
Jan 1, 2016
Actual Primary Completion Date :
Feb 23, 2021
Actual Study Completion Date :
Feb 23, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cognitive training program 1

This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.

Behavioral: Cognitive training program
8 week cognitive training program

Experimental: Cognitive training program 2

This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.

Behavioral: Cognitive training program
8 week cognitive training program

Outcome Measures

Primary Outcome Measures

  1. Change in brain structure [8 weeks]

    Gray matter structure will be assessed before and after the 8 week programs.

  2. Change in brain activity during a memory test [8 weeks]

    Brain activity during a memory task will be assessed before and after the 8 week programs.

Secondary Outcome Measures

  1. Blood markers [baseline, 8 weeks, 12 and 24 months]

    Blood will be collected at baseline, 8 weeks, 12 and 24 months. This will be used to assess changes in various biomarkers that are known to change with aging.

  2. Change in cognition [2 years]

    Participants will complete a series of memory and attention tests at 6 time-points: baseline, 2 months, 6 months, 12 months 18 months and 24 months.

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 65-80 years of age

  • Right-handed

Exclusion Criteria:
  1. Lifetime history of schizophrenia or psychosis. Any other Axis I diagnosis in the past 12 months.

  2. Subjects must not endorse suicidality, homicidality or self-destructive acts or urges as assessed through a structured clinical interview (SCID)

  3. History of seizure or significant head trauma (i.e., extended loss of consciousness, neurological sequelae, or known structural brain lesion).

  4. Neurological or medical conditions that would interfere with study procedures or confound results, such as conditions that alter cerebral blood flow or metabolism.

  5. Use of psychotropic medications within 12 months prior to study.

  6. Daily use of any medication that alters neural metabolism or blood flow.

  7. Any concurrent psychotherapy.

  8. Having taken no more than 8 meditation classes (or related practices such as yoga, Tai Chi, or Chi Gong) of any kind in the past 6 months, or more than 15 classes in the past 12 months.

  9. Pregnancy.

  10. Metallic implants or devices contraindicating magnetic resonance imaging.

  11. Claustrophobia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusetts General Hospital Boston Massachusetts United States 02129

Sponsors and Collaborators

  • Massachusetts General Hospital
  • National Institutes of Health (NIH)
  • National Institute on Aging (NIA)

Investigators

  • Principal Investigator: Sara Lazar, PhD, Mass. General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sara W Lazar, Associate Research Scientist, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT02628548
Other Study ID Numbers:
  • 2015P001851
  • R01AG048351
First Posted:
Dec 11, 2015
Last Update Posted:
Feb 25, 2021
Last Verified:
Feb 1, 2021

Study Results

No Results Posted as of Feb 25, 2021